EUVIMEDEUVIMED entdecken
Crossref

The Effect of Anti-Tumor Necrosis Factor Therapy on The Plasma Atherogenic Index in Rheumatic Diseases

Osman Cure, Bayram Kizilkaya, Serpil Ciftel, Filiz Mercantepe iD

Metabolic Syndrome and Related Disorders · 2024

DOI: 10.1089/met.2023.0237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metabolic Syndrome and Related Disorders, 2024. Verfasst von Osman Cure und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey. Hauptthemen laut MEDLINE: Atherosclerosis, Rheumatic Diseases, Tumor Necrosis Factor-alpha. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The risk of atherosclerosis is increased in individuals with rheumatological disease. The objective of this study is to examine the heightened susceptibility to atherosclerosis in persons afflicted with rheumatological disorders. This study aimed to assess the impact of anti-tumor necrosis factor (anti-TNF) medication on the plasma atherogenic index (PAI) in persons diagnosed with rheumatological disease.

Methods

This study used a retrospective cross-sectional design to investigate a cohort of 136 patients with rheumatological disease who were undergoing anti-TNF therapy (Group 1), as well as a comparison group of 117 patients getting conventional therapy (Group 2). Measurements of PAI were conducted at the initial baseline and again at the sixth month of treatment.

Results

Initially, there was no statistically significant disparity observed in PAI values between the two cohorts. After a period of 6 months, a notable reduction in PAI was identified in the group receiving anti-TNF medication (P = 0.01), while no significant alteration was detected in the group receiving conventional treatment.

Conclusion

It provides findings showing that anti-TNF therapy can reduce the PAI in individuals with rheumatological disease. This may indicate a potential cardiovascular protective effect of anti-TNF therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisRheumatic DiseasesTumor Necrosis Factor-alphaHumansMaleRetrospective StudiesFemaleMiddle AgedCross-Sectional StudiesAdultAntirheumatic AgentsAgedTreatment Outcome

Stichwörter der Autor:innen

anti-TNFatherogenic indexatherosclerosiscardiovascular riskrheumatological disease

Substanzen

Tumor Necrosis Factor-alphaAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
  • Department of Internal Medicine, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
  • Department of Endocrinology and Metabolism, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.
  • Department of Endocrinology and Metabolism, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.

ORCID-Profile: Filiz Mercantepe

Zitieren

APA

Cure, O., Kizilkaya, B., Ciftel, S., & Mercantepe, F. (2024). The Effect of Anti-Tumor Necrosis Factor Therapy on The Plasma Atherogenic Index in Rheumatic Diseases. Metabolic Syndrome and Related Disorders. https://doi.org/10.1089/met.2023.0237

Vancouver

Cure O, Kizilkaya B, Ciftel S, Mercantepe F. The Effect of Anti-Tumor Necrosis Factor Therapy on The Plasma Atherogenic Index in Rheumatic Diseases. Metabolic Syndrome and Related Disorders. 2024. doi:10.1089/met.2023.0237

BibTeX
@article{Cure2024,
  author = {Cure, Osman and Kizilkaya, Bayram and Ciftel, Serpil and Mercantepe, Filiz},
  title = {The Effect of Anti-Tumor Necrosis Factor Therapy on The Plasma Atherogenic Index in Rheumatic Diseases},
  journal = {Metabolic Syndrome and Related Disorders},
  year = {2024},
  doi = {10.1089/met.2023.0237}
}
Kostenlos starten →